GIM
Granahan Investment Management Portfolio holdings
AUM
$2.46B
This Quarter Return
-6.94%
1 Year Return
+66.36%
3 Year Return
+183.04%
5 Year Return
+309.49%
10 Year Return
+1,968.52%
AUM
$2.01B
AUM Growth
+$2.01B
(-16%)
Cap. Flow
-$116M
Cap. Flow
% of AUM
-5.76%
Top 10 Holdings %
Top 10 Hldgs %
30.28%
Holding
198
New
18
Increased
59
Reduced
82
Closed
39
Top Buys
| 1 |
Descartes Systems
DSGX
|
$33.5M |
| 2 |
Comfort Systems
FIX
|
$22M |
| 3 |
Semtech
SMTC
|
$17.1M |
| 4 |
Centrus Energy
LEU
|
$13.4M |
| 5 |
SPS Commerce
SPSC
|
$13.4M |
Top Sells
| 1 |
Axon Enterprise
AXON
|
$40.7M |
| 2 |
Shift4
FOUR
|
$23M |
| 3 |
Evolent Health
EVH
|
$21.9M |
| 4 |
Globant
GLOB
|
$15.8M |
| 5 |
Magnite
MGNI
|
$11M |
Sector Composition
| 1 | Technology | 34.72% |
| 2 | Industrials | 17.74% |
| 3 | Healthcare | 12.99% |
| 4 | Consumer Discretionary | 9.74% |
| 5 | Financials | 9.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Stoke Therapeutics
STOK
$1.08B
| $4.39M | 0.22% |
660,430
+92,741
| +16% | +$617K |
|
102
Cellebrite
CLBT
$4.04B
| $4.37M | 0.22% |
225,040
-2,357
| -1% | -$45.8K |
|
103
McGrath RentCorp
MGRC
$2.99B
| $4.35M | 0.22% |
39,043
-2,490
| -6% | -$277K |
|
104
Ciena
CIEN
$13.3B
| $4.34M | 0.22% |
71,783
+24,325
| +51% | +$1.47M |
|
105
Vital Farms
VITL
$2.25B
| $4.23M | 0.21% |
138,691
-12,656
| -8% | -$386K |
|
106
Natera
NTRA
$22.8B
| $4.13M | 0.21% |
29,234
-26,208
| -47% | -$3.71M |
|
107
Chart Industries
GTLS
$8.95B
| $4.06M | 0.2% |
28,151
-11,138
| -28% | -$1.61M |
|
108
Apogee Therapeutics
APGE
$2.27B
| $4.05M | 0.2% |
108,340
+15,486
| +17% | +$579K |
|
109
Merus
MRUS
$5.04B
| $4.03M | 0.2% |
95,720
-8,842
| -8% | -$372K |
|
110
Agios Pharmaceuticals
AGIO
$2.33B
| $3.87M | 0.19% |
132,108
+16,421
| +14% | +$481K |
|
111
Apellis Pharmaceuticals
APLS
$3.49B
| $3.84M | 0.19% |
175,696
+21,278
| +14% | +$465K |
|
112
Arcus Biosciences
RCUS
$1.23B
| $3.76M | 0.19% |
479,590
+133,497
| +39% | +$1.05M |
|
113
PROS Holdings
PRO
$725M
| $3.72M | 0.19% |
195,622
-138,733
| -41% | -$2.64M |
|
114
Boot Barn
BOOT
$5.51B
| $3.48M | 0.17% |
32,402
-50,834
| -61% | -$5.46M |
|
115
Intellia Therapeutics
NTLA
$1.25B
| $3.38M | 0.17% |
475,946
+169,436
| +55% | +$1.2M |
|
116
Astera Labs
ALAB
$29.3B
| $3.29M | 0.16% |
+55,057
| New | +$3.29M |
|
117
RxSight
RXST
$359M
| $3.28M | 0.16% |
129,721
+9,488
| +8% | +$240K |
|
118
Novanta
NOVT
$3.96B
| $3.27M | 0.16% |
25,610
+1,166
| +5% | +$149K |
|
119
PTC
PTC
$25.3B
| $3.15M | 0.16% |
20,299
-20,467
| -50% | -$3.17M |
|
120
Silicon Laboratories
SLAB
$4.26B
| $3.06M | 0.15% |
27,216
-19,247
| -41% | -$2.17M |
|
121
Immunovant
IMVT
$2.92B
| $2.94M | 0.15% |
172,316
+22,920
| +15% | +$392K |
|
122
Immunome
IMNM
$867M
| $2.82M | 0.14% |
419,271
+105,032
| +33% | +$707K |
|
123
FIVE9
FIVN
$2.04B
| $2.79M | 0.14% |
102,682
-60,975
| -37% | -$1.66M |
|
124
AnaptysBio
ANAB
$609M
| $2.72M | 0.14% |
146,491
+40,412
| +38% | +$751K |
|
125
Celestica
CLS
$24.1B
| $2.56M | 0.13% |
32,528
+4,553
| +16% | +$359K |
|